



(19) REPUBLIKA HRVATSKA
DRŽAVNI ZAVOD ZA
INTELEKTUALNO VLASNIŠTVO

(10) Identifikator
dokumenta:

HR P20201916 T1



HR P20201916 T1

(12) **PRIJEVOD PATENTNIH ZAHTEJEVA
EUROPSKOG PATENTA**

(51) MKP:

C07D 403/12 (2006.01)
C07D 401/14 (2006.01)
C07D 231/14 (2006.01)
C07D 401/04 (2006.01)
C07D 403/04 (2006.01)
C07D 405/12 (2006.01)
C07D 413/04 (2006.01)
C07D 413/12 (2006.01)
C07D 417/12 (2006.01)
A61P 7/02 (2006.01)
A61K 31/415 (2006.01)

(46) Datum objave prijevoda patentnih zahtjeva: 22.01.2021.

(21) Broj predmeta: P20201916T

(22) Datum podnošenja zahtjeva u HR: 01.12.2020.

(86) Broj međunarodne prijave: PCT/US2015019535
Datum podnošenja međunarodne prijave: 09.03.2015.

(96) Broj europske prijave patenta: EP 15759254.4
Datum podnošenja europske prijave patenta: 09.03.2015.

(87) Broj međunarodne objave: WO 2015134998
Datum međunarodne objave: 11.09.2015.

(97) Broj objave europske prijave patenta: EP 3113772 A1
Datum objave europske prijave patenta: 11.01.2017.

(97) Broj objave europskog patenta: EP 3113772 B1
Datum objave europskog patenta: 09.09.2020.

(31) Broj prve prijave: 201461949808 P (32) Datum podnošenja prve prijave: 07.03.2014. (33) Država ili organizacija podnošenja prve prijave: US
201461981515 P 18.04.2014. US

(73) Nositelj patenta: BioCryst Pharmaceuticals, Inc., 4505 Emperor Blvd., Durham, NC 27703, US

(72) Izumitelji: Pravin L. Kotian, AL 35226, US
Yarlagadda S. Babu, AL 35244, US
Minwan Wu, AL 35226, US
Venkat R. Chintareddy, AL 35216, US
Satish V. Kumar, AL 35244, US
Weihe Zhang, AL 35226, US











(74) Zastupnik: ZMP IP d.o.o., 10000 Zagreb, HR


(54) Naziv izuma: TRIFLUOROMETIL SUPSTITUIRANI PIRAZOLI KAO INHIBITORI KALIKREINA U LJUDSKOJ PLAZMI


HR P20201916 T1


PATENTNI ZAHTJEVI







1. Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je navedeni spoj odabran iz skupine koja sadrži:


















































2. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što je navedeni spoj odabran iz skupine koju čine:










i


5


3. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutska prihvatljiva sol, naznačen time što je navedeni spoj odabran iz skupine koju čine:















































- 5 4. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je navedeni spoj odabran iz skupine koju čine:










5. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je navedeni spoj odabran iz skupine koju čine:






- 5 6. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj odabran iz skupine koju čine







7. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj odabran iz skupine koju čine




5

8. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj odabran iz skupine koju čine







9. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj odabran iz skupine koju čine




5

10. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj odabran iz skupine koju čine







11. Spoj prema patentnom zahtjevu 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je spoj odabran iz skupine koju čine



5



12. Spoj prema patentnom zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što navedeni spoj ima formulu:



- 10 13. Spoj prema patentnom zahtjevu 12, naznačen time što je spoj (+)-enantiomer.

14. Spoj prema patentnom zahtjevu 12, naznačen time što je spoj (-)-enantiomer.
15. Spoj prema bilo kojem od patentnih zahtjeva 12-14, naznačen time što je spoj hidrokloridna sol.
16. Spoj prema bilo kojem od patentnih zahtjeva 12-14, naznačen time što je spoj bis (hidrokloridna) sol.
- 5 17. Farmaceutski pripravak, naznačen time što sadrži spoj prema bilo kojem od patentnih zahtjeva 1-16, ili njegovu farmaceutski prihvatljivu sol, i farmaceutski prihvatljiv nosač, po izboru pri čemu je farmaceutski pripravak formuliran za parenteralnu primjenu ili oralnu primjenu, po izboru pri čemu je farmaceutski pripravak formuliran za profilaktički ili terapijski tretman bolesti ili stanja u kojem je poželjno smanjiti aktivnost kalikreina u plazmi; pri čemu je bolest ili stanje odabrano iz skupine koja se sastoji od moždanog udara, upale, reperfuzijske ozljede, akutnog infarkta miokarda, duboke venske tromboze, stanja nakon fibrinolitičkog liječenja, angine, edema, angioedema, nasljednog angioedema, sepse, artritisa, krvarenja, gubitka krvi tijekom kardiopulmonalne premosnice, upalne bolesti crijeva, dijabetes melitusa, retinopatije, dijabetične retinopatije, dijabetičnog makularnog edema, dijabetičke makularne degeneracije, makularnog edema povezanog sa starenjem edema, makularne degeneracije povezane sa starenjem, proliferativne retinopatije, neuropatije, hipertenzije, edema mozga, povećanog izlučivanja albumina, makroalbuminurije, te nefropatije.
- 10 18. Spoj prema bilo kojem od patentnih zahtjeva 1-16, ili njegova farmaceutski prihvatljiva sol, naznačen time što je za uporabu za liječenje ili sprječavanje bolesti ili stanja u kojem je poželjno smanjiti aktivnost kalikreina u plazmi; pri čemu je bolest ili stanje odabrano iz skupine koja se sastoji od moždanog udara, upale, reperfuzijske ozljede, akutnog infarkta miokarda, duboke venske tromboze, stanja nakon fibrinolitičkog liječenja, angine, edema, angioedema, nasljednog angioedema, sepse, artritisa, krvarenja, gubitka krvi tijekom kardiopulmonalne premosnice, upalne bolesti crijeva, dijabetes melitusa, retinopatije, dijabetične retinopatije, dijabetičnog makularnog edema, dijabetičke makularne degeneracije, makularnog edema povezanog sa starenjem edema, makularne degeneracije povezane sa starenjem, proliferativne retinopatije, neuropatije, hipertenzije, edema mozga, povećanog izlučivanja albumina, makroalbuminurije, te nefropatije.
- 15 19. Spoj za uporabu prema patentnom zahtjevu 18, naznačen time što je bolest ili stanje angioedem.
- 20 20. Spoj za uporabu prema patentnom zahtjevu 18, naznačen time što je bolest ili stanje nasljedni angioedem.
- 25 21. Spoj prema bilo kojem od patentnih zahtjeva 1-16, ili njegova farmaceutski prihvatljiva sol, naznačen time što je za uporabu kao lijek.